Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

NGM Bio gains license to Horizon cell line
April 2020
SHARING OPTIONS:

CAMBRIDGE, U.K.—Horizon Discovery Group plc has licensed its gene-edited glutamine synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line to NGM Biopharmaceuticals Inc., the company announced last quarter. The multi-product use license covers the use of the cell line for the research and development of biotherapeutics.
 
Dirk Gewert, business unit director at Horizon Discovery, commented in part that, “Horizon aims to empower organizations of all sizes, from large pharmaceutical companies to clinical-stage biotechs and early-stage startups, to drive efficiencies in biotherapeutic manufacturing. To date, our complete CHO expression system has been licensed to over 50 companies globally, with a number of biotherapeutics expressed in these cells having progressed to investigational new drug filings.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.